Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.
Vaccination activity and safety of inactivated influenza centrifugal divaccine have been studied in groups of subjects aged 18 to 22, 15 to 16, and 9 to 14 years. The vaccine tested contained either a standard dose (6-8 micrograms) or double a dose (12-16 micrograms) of the haemagglutinin (HA) of influenza viruses A(H1N1) and A(H3N2). The double antigenic load of the vaccine did not enhance its reactogenicity for adults or adolescents aged 15 to 16 years. It enhanced, however, the production of antihaemagglutinine antibodies to the vaccine strains. The range of the antibodies formed and their persistence were independent on the virus dose. The increased dose (12-16 micrograms) of HA decreased the humoral immune response in school children aged from 11 to 14 years. Neither standard nor double dose of the vaccine caused any changes in the biochemical or haematological parameters of blood and urine. No allergic response was registered by the indirect mast cell degranulation (IMCD) test in rats.
Subbotina
T I
TI
Leningrad Research Institute of Vaccines and Sera, U.S.S.R.
Tenkova
T V
TV
Sidorova
L V
LV
Shpilyuk
G F
GF
Drinevsky
V P
VP
Voitsekhovskaya
E M
EM
Konstantinov
V K
VK
Sominina
A A
AA
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002499:Centrifugation, Density Gradient; D002648:Child; D006389:Hemagglutinins, Viral / Q000276:immunology; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000302:isolation & purification; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification
D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated